Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 50 of 97, showing 5 Applications out of 482 total, starting on record 246, ending on 250

# Protocol No Study Title Investigator(s) & Site(s)

246.

ECCT/18/10/03   UMBIFLOW
    Prevalence and outcomes of abnormal continuous wave Doppler flow indices in unselected obstetric populations in low- and middle-income countries: The Umbiflow International Study.   
Principal Investigator(s)
1. Prof Zahida Parveen Qureshi
Site(s) in Kenya
1. Mbagathi District Hospital (Nairobi City county)
2. St. Mary\'s Hospital (Nairobi City county)
3. Kenyatta National Hospital (Nairobi City county)
 
View

247.

ECCT/14/06/01   ACTG -5279
    Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection   
Principal Investigator(s)
1. Dr. Kevin N/A Cain
Site(s) in Kenya
1. KEMRI/WRP CRS (Kericho county)
2. Moi University Clinical Research Center CRS ()12601 (Uasin Gishu county)
 
View

248.

ECCT/20/12/01   KU ‘TIBA VENT\'
    Phase I/II, Open Label Randomized Controlled Trial Evaluating Safety of  'KU TIBA VENT" For Mechanical Ventilation in Patients With Respiratory Failure During Weaning Phase   Abstract   KU TIBA VENT   There is ongoing pandemic caused by SARS-Cov-2, commonly referred to us COVID-19 that started in China in December 2019. The patients develop acute respiratory failure requiring machine assisted breathing. However, due to the huge numbers affected patients, the demand for mechanical ventilators outstrip supply worldwide. This is especially so in Kenya with poor health systems. In response to the increased demand for mechanical ventilators, a group of students plus their lecturer mentors at Kenyatta University responded by designing and producing a ‘TIBA VENT” from locally available materials. The design and production processes have been evaluated by the Kenya Bureau of Standards and found to be in conformity with the countries standards. We have designed a protocol to guide clinical validation before registration by Pharmacy and Poisons Board as part of requirement for commercialization. The main objective of this clinical validation is to assess the dependability and reliability of the device when connected to patients in the intensive care Unit. The secondary end points are to assess the functionality of the control variables, the trigger settings as well as user concerns to facilitate design modifications before roll out. The clinical validation will be done at Kenyatta University Teaching, Research and Referral Hospital (KUTRRH). This is a phase II of study with expected duration of 14 days and enrolling at least 4 patients. The sponsor for the study is the Kenyatta University. The information obtained will assist in design modifications before commercialization. This is an example of homegrown innovation.   
Principal Investigator(s)
1. Gordon Oluoch Ogweno
Site(s) in Kenya
Kenyatta University Teaching Research and Referral Hospital (KUTRRH)
 
View

249.

ECCT/20/09/01   PrEP in Pharmacy - PILOT STUDY
    Pharmacy delivery to expand the reach of PrEP in Kenya: Pilot study       
Principal Investigator(s)
1. Kenneth Kairu Ngure
Site(s) in Kenya
KEMRI-CCR PHRD (THIKA) PROJECT
 
View

250.

ECCT/23/02/05   Pharmacy PrEP cRCT
    Pharmacy delivery to expand the reach of PrEP in Kenya: cluster-randomized control trial   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Kenneth Ngure
Site(s) in Kenya
1. Kenya Medical Research Institute, Center for Microbiology Research, Research Care and Training Programme (KEMRI-CMR-RCTP) research center (Kisumu county)
2. Kenya Medical Research Institute, Center for Clinical Research, Partners in Health and Research Development (KEMRI-CCR-PHRD) research center (Kiambu county)
 
View